Duvelisib R enantiomer
≥98%
- Product Code: 100398
CAS:
1261590-48-0
| Molecular Weight: | 416.86 g./mol | Molecular Formula: | C₂₂H₁₇ClN₆O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Duvelisib R enantiomer is primarily utilized in the field of oncology, specifically for the treatment of certain types of blood cancers. It is an inhibitor of phosphoinositide 3-kinase (PI3K), which plays a critical role in the growth and survival of cancer cells. By targeting the PI3K delta and gamma isoforms, this compound helps to disrupt signaling pathways that are essential for the proliferation of malignant B-cells. It has shown efficacy in the management of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Additionally, it is being investigated for its potential in treating other hematologic malignancies, offering a therapeutic option for patients who have limited responses to conventional therapies. Its application underscores the importance of targeted therapies in improving outcomes for cancer patients.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿14,877.00 |
+
-
|
| 0.010 | 10-20 days | ฿24,624.00 |
+
-
|
Duvelisib R enantiomer
Duvelisib R enantiomer is primarily utilized in the field of oncology, specifically for the treatment of certain types of blood cancers. It is an inhibitor of phosphoinositide 3-kinase (PI3K), which plays a critical role in the growth and survival of cancer cells. By targeting the PI3K delta and gamma isoforms, this compound helps to disrupt signaling pathways that are essential for the proliferation of malignant B-cells. It has shown efficacy in the management of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Additionally, it is being investigated for its potential in treating other hematologic malignancies, offering a therapeutic option for patients who have limited responses to conventional therapies. Its application underscores the importance of targeted therapies in improving outcomes for cancer patients.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :